ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2338

Validation of a Claims Algorithm to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis

Margaret Guthrie1, Ankoor Shah 2, Leonard Lobo 3, Jim Oates 4, Cassie Clinton 1, Narender Annapureddy 5, Fenglong Xie 6, Bryant England 7 and Jeffrey Curtis 1, 1University of Alabama at Birmingham, Birmingham, AL, 2Duke University, Durham, NC, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, 4Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC, 5Vanderbilt University, Nashville, TN, 6University of Alabama at Birmingham, Birmingham, 7VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: interstitial lung disease and Medicare, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is an increasingly important problem for patients with Rheumatoid Arthritis (RA). However, current approaches to ILD case finding are suboptimal or have been evaluated only in limited settings. Our objective was to develop, refine, and validate a claims-based algorithm to identify both prevalent and incident ILD in a cohort of RA patients enrolled in Medicare compared to the gold standard of medical record review.

Methods: We used Medicare administrative claims data 2006-2015 to derive a cohort of RA patients and then identified suspected ILD using variations on several features of the data. These included various ILD diagnosis codes using ICD9/10 coding, evaluation by pulmonologists and rheumatologists, occurrence of chest CT, lung biopsy results, and pulmonary function tests. Suspected ILD cases were evaluated at five participating medical centers: Duke, Medical University of South Carolina, University of Alabama at Birmingham, University of North Carolina, and Vanderbilt. The centers identified patients in their medical systems using either a search tool run against a central data warehouse or repository (e.g. i2b2) or a local ILD registry. Medical record reviewers abstracted the clinical data, including physician notes, CT scan and imaging results, lung pathology reports, and pulmonary Function tests (PFTs), into a case report form which was then adjudicated by two ILD experts (pulmonology and rheumatology). Discordance in adjudication was resolved by consensus. The positive predictive value (PPV), the primary outcome of the study, was calculated for each ILD algorithm for both prevalent and incident ILD and 95% confidence interval (CI) using a binomial distribution.

Results: We identified 264 linkable RA patients with sufficient data to evaluate for ILD. Overall, 115 (44.6%) of suspected cases (based on a highly sensitive case finding approach) were classified as ILD. The most common diagnosis codes identified in this initial search were 515 (Postinflammatory pulmonary fibrosis, 33%), 518.89 (Other disorders of lung, 24%), 714.81 (rheumatoid lung, 9%), 793.19 (Other nonspecific abnormal finding of lung field, 8%), and J84 (Other interstitial pulmonary diseases with fibrosis, 6%). 516 (Other alveolar and parietoalveolar pneumonopathy, 3%). A total of 36.0% of cases were hospitalized (4.9% primary diagnosis code, 31.1% non-primary diagnosis code), and the remainder were outpatient. The best performing algorithm for prevalent ILD had a PPV of 77% (95% CI 67%-85%) and for incident ILD was 74.2% (95% CI 58.9-89.6%).

Conclusion: ILD case finding in RA patients using administrative claims data is feasible and has reasonable accuracy. Both prevalent and incident ILD can be identified.


Disclosure: M. Guthrie, None; A. Shah, Beohringer-Ingelheim, 2, Bristol-Myers Squibb, 2, Reata, 2; L. Lobo, None; J. Oates, None; C. Clinton, None; N. Annapureddy, None; F. Xie, None; B. England, None; J. Curtis, AbbVie, 2, 5, Abbvie, 2, 5, AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, 2, 5, Amgen, 2, 5, Amgen Inc., 2, 5, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 2, 5, Genentech, 2, 5, Janseen, 5, Janssen, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Myriad, 2, 5, Patient Centered Outcomes Research Insitute (PCORI), 2, Pfizer, 2, 5, Radius Health, Inc., 9, Regeneron, 2, 5, Roche, 2, 3, 5, Roche/Genentech, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Guthrie M, Shah A, Lobo L, Oates J, Clinton C, Annapureddy N, Xie F, England B, Curtis J. Validation of a Claims Algorithm to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/validation-of-a-claims-algorithm-to-identify-interstitial-lung-disease-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-a-claims-algorithm-to-identify-interstitial-lung-disease-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology